Resources
48 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/5/2024 (updated 5/7/2024)
The U.S. Department of Health & Human Services released details of a plan for more than 200 actions across the federal government to address high rates of suicide.
Posted 5/5/2024 (updated 5/7/2024)
The MaineHealth Substance Use Training team has created a toolkit for extended-release injectable buprenorphine (Sublocade).
Posted 4/4/2024 (updated 4/18/2024)
If you or someone else is in immediate danger, call 911 to seek immediate assistance.
Below are resources you can contact if you are seeking assistance or information. All resources are intended for informational purposes only.
Posted 5/26/2021 (updated 4/10/2024)
Opioid dependence is a chronic relapsing disorder with considerable individual and global public health burden. The current standard of care for opioid dependence includes treatment with methadone or sublingual (SL) buprenorphine or buprenorphine-naloxone (hereafter, buprenorphine), combined with psychosocial and behavioral support. Both medications are associated with reductions in mortality, illicit opioid use, bloodborne viral infections, and criminal behavior as well as better cost-effectiveness than no treatment or psychosocial treatment alone. Buprenorphine is a partial μ-opioid receptor agonist, enabling office-based treatment for nonsupervised or take-home use of the medication. However, SL formulations of buprenorphine are prone to nonmedical use (eg, injecting, diversion), prompting models of care, particularly in the early phases of treatment, requiring regular attendance at clinics or pharmacies for administration of doses.
Posted 3/25/2021 (updated 4/5/2024)
Posted 1/26/2021 (updated 4/4/2024)
This webinar was a continuation of the previously scheduled Grant Writing Strategies Webinar- Part 1. Pam Baston provided more practical examples of grant writing strategies and techniques from many successful proposals.
Posted 1/12/2021 (updated 4/4/2024)
During this webinar, Pam Baston, Technical Expert Lead with JBS International, Inc., provided practical examples of grant writing strategies and techniques from many successful proposals. This session included tips for: Reviewing the funding opportunity application, Creating the template and action list, Assembling a team & Creating responsive and competitive proposal sections
Posted 11/10/2021 (updated 4/3/2024)
The WICHE Behavioral Health Program, in partnership with staff at the Suicide Prevention Resource Center (SPRC), developed the Suicide Prevention Toolkit for Primary Care Practices to provide the necessary tools and information needed to primary care practices and clinics to identify and address the critical needs of suicidal patients. This revised edition is fully aligned with Zero Suicide, the nationally recognized, evidence-based suicide prevention framework.
Posted 11/9/2021 (updated 4/3/2024)
This workshop will explore the link between Adverse Childhood Experiences (ACEs) of individuals with substance use concerns and its impact on their development. We will explore the experiences, perceptions, beliefs, and behaviors that may present challenges in development. We will discuss practical, trauma-informed, outcome-driven strategies that improve the outcomes.
Posted 10/5/2021 (updated 4/3/2024)
This webinar focused on the crucial role of the emergency department (ED) in recognizing and treating opioid use disorder (OUD) patients with evidence-based medications for addiction treatment. Gail D’Onofrio, MD, discussed her pioneering work in creating the evidence for initiating ED buprenorphine treatment with ED patients presenting with opioid use disorder. Overall, the opioid epidemic intertwined with the COVID-19 pandemic has greatly escalated the need to mitigate the morbidity and mortality associated with the rising rate of fentanyl use. Data supporting the use of buprenorphine in the ED setting as well as the consequences of not initiating treatment will be discussed. While the use of ED prescribed buprenorphine has increased, universal adoption has lagged. Barriers to implementation of ED buprenorphine were discussed as well as strategies to overcome these challenges. Components of successful integration of an ED program with community partnerships was outlined. Current research by emergency physicians regarding innovative strategies such as high-dose buprenorphine inductions and use of extended release 7-day formulation of buprenorphine will be discussed. Initiation buprenorphine effectively, reduces withdrawal symptoms, improves adherence to treatment, and saves lives.